These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 16177289

  • 1. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 2. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT.
    Am J Ther; 2007 Sep; 14(4):322-7. PubMed ID: 17667204
    [Abstract] [Full Text] [Related]

  • 3. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Sep; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 4. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL, McKenzie RS, Fastenau J, Piech CT.
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [Abstract] [Full Text] [Related]

  • 5. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D, George MJ, Harrison LB.
    Cancer; 2003 Sep 01; 98(5):1072-9. PubMed ID: 12942577
    [Abstract] [Full Text] [Related]

  • 6. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C.
    Curr Med Res Opin; 2007 Aug 01; 23(8):1931-7. PubMed ID: 17624232
    [Abstract] [Full Text] [Related]

  • 7. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Aug 01; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 8. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul 01; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 9. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 01; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct 01; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 11. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep 01; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 12. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
    Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT.
    Curr Med Res Opin; 2006 May 01; 22(5):837-42. PubMed ID: 16709305
    [Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 May 01; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 14. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 01; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 15. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 01; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 16. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 01; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 17. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N, Fouda M.
    Hematology; 2007 Dec 01; 12(6):533-41. PubMed ID: 17852440
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 01; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 19. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G.
    Anticancer Res; 2005 Sep 01; 25(1B):669-74. PubMed ID: 15816644
    [Abstract] [Full Text] [Related]

  • 20. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B, van de Werf PR, Melissant CF, Brok RG.
    Lung Cancer; 2007 Oct 01; 58(1):104-11. PubMed ID: 17601632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.